Market Overview

Pradaxa Lawsuits Launched Against Drug Maker


(EMAILWIRE.COM, October 26, 2012 ) New York, NY A number of Pradaxa lawsuits have been filed against drug maker Boehringer Ingelheim over its blockbuster blood thinner, alleging that patients and doctors were not properly warned of its bleeding risks. Over the past several months, it is believed that at least 21 cases have been filed across the country, and it is likely that hundreds of more actions will be pursued, according to attorneys involved in the litigation. As the Pradaxa lawsuits move forward, the lawyers working with are continuing to provide a free legal consultation to patients who suffered internal bleeding while taking the drug, as well as loved ones acting on their behalf. If you or a loved one suffered a cerebral hemorrhage, gastrointestinal bleed or other bleeding event while taking Pradaxa, visit to have your bleeding injury claim reviewed, at no cost to you. You may be able to seek compensation for medical bills and other damages stemming from your injuries.

In the most recent development in the Pradaxa lawsuits, a panel of federal judges entered an order which consolidated all current and future federally-filed cases to a single court. The consolidation of the cases is likely to allow consistency in the rulings and expedite the litigation, which will be overseen by the Honorable Judge David Herndon who is well-known for expediting the litigation involving the birth control pill Yaz. According to the Transfer Order, centralizing the litigation was appropriate because all the actions share common questions of fact arising from allegations that the plaintiffs suffered severe bleeds or other injuries due to their use of Pradaxa; the drugs maker did not properly warn doctors of the risks associated with the drug, including the potential for life-threatening or fatal bleeds; and that there is no antidote to counteract the drugs anti-clotting effects.

Used to prevent strokes and blood clots in atrial fibrillation patients, Pradaxa was approved in October 2010. Shortly thereafter, in Dec. 2011, the FDA announced that it would review reports of serious and sometimes fatal bleeds in patients taking the anti-coagulant. While all blood thinners pose a risk of bleeds, it has been alleged that Pradaxa is particularly dangerous because, unlike older drug Coumadin, there is no antidote to reverse its anticlotting effects, leaving doctors without an effective means to treat and stabilize patients who experienced uncontrolled bleeding on Pradaxa.

For more information on Pradaxa lawsuits and to receive a free evaluation of your injuries, please visit today.

About Class

Class is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit today for a no cost, no obligation case evaluation and information about your consumer rights.

Hannah Armstrong


This is a press release. Press release distribution and press release services by EmailWire.Com:

Source: EmailWire.Com

View Comments and Join the Discussion!